MARKET

MREO

MREO

Mereo Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.210
+0.040
+3.42%
Pre Market: 1.160 -0.05 -4.13% 08:31 08/11 EDT
OPEN
1.200
PREV CLOSE
1.170
HIGH
1.210
LOW
1.145
VOLUME
2.20K
TURNOVER
--
52 WEEK HIGH
2.930
52 WEEK LOW
0.3010
MARKET CAP
141.55M
P/E (TTM)
7.42
1D
5D
1M
3M
1Y
5Y
BRIEF-Mereo Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
BRIEF-Mereo Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
Reuters · 07/05 20:10
Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Mereo BioPharma Group (NASDAQ:MREO) <a href="https://seekingal...
Seekingalpha · 07/05 20:08
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has received...
GlobeNewswire · 07/05 20:01
Mereo BioPharma Regains Compliance With Nasdaq Minimum Bid Price
MT Newswires · 07/05 16:23
ASML Holding, Stellantis, STMicroelectronics among premarket losers' pack
Siyata Mobile (SYTA) -11%. Revelation Biosciences (<a href="https://se...
Seekingalpha · 07/05 12:26
Anebulo, Tenon top healthcare gainers; BioSig, Rigel lead losers' pack
Gainers: Anebulo Pharmaceuticals (ANEB) +32%. Tenon Medical (TNON) +19%. PolarityTE (PTE) +14%. TRACON Pharmaceuticals (TCON) +14%. Bausch Health (BHC) +13%. Losers: BioSig Technologies (BSGM) -26%. Rigel Pharmaceuticals (RIGL) -8%. Valneva (VALN) -8%. Mer...
Seekingalpha · 06/24 14:05
F-star, Valneva top healthcare gainers; Applied Therapeutics, Mereo lead losers' pack
Gainers: F-star Therapeutics FSTX +57%. Valneva VALN +23%. Nutriband NTRB +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics APLT -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) -12%. bluebird bio (...
Seekingalpha · 06/23 14:04
22nd Century, Wave Life top healthcare gainers; while Athira, Neptune Wellness lead losers' pack
Gainers: 22nd Century Group (XXII) +29%. Wave Life Sciences (WVE) +16%. Codex DNA (DNAY) +13%. F-star Therapeutics (FSTX) +12%. Sorrento Therapeutics (SRNE) +12%. Losers: Athira Pharma (ATHA) -70%. Neptune Wellness Solutions (NEPT) -32%. 4D pharma (LBPS) -...
Seekingalpha · 06/22 14:03
More
No Data
Learn about the latest financial forecast of MREO. Analyze the recent business situations of Mereo Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MREO stock price target is 7.04 with a high estimate of 8.05 and a low estimate of 5.03.
High8.05
Average7.04
Low5.03
Current 1.210
EPS
Actual
Estimate
-5.24-3.93-2.62-1.31
2018/12
2019/06
2019/12
2020/06
2020/12
Institutional Holdings
Institutions: 71
Institutional Holdings: 85.97M
% Owned: 73.49%
Shares Outstanding: 116.98M
TypeInstitutionsShares
Increased
22
3.49M
New
3
10.19M
Decreased
12
3.44M
Sold Out
15
1.97M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Peter Fellner
Chief Executive Officer/Director
Denise Scots-Knight
Vice Chairman/Non-Executive Independent Director
Michael Wyzga
Chief Financial Officer
Christine Fox
Senior Vice President
Suba Krishnan
Senior Vice President
Jackie Parkin
Chief Scientific Officer
John Lewicki
General Counsel/Secretary
Charles Sermon
Other
Alexandra Hughes-wilson
Other
Alastair Mackinnon
Other
John Richard
Non-Executive Director
Anne Hyland
Non-Executive Director
Pierre Jacquet
Non-Executive Independent Director
Jeremy Bender
Non-Executive Independent Director
Anders Ekblom
Non-Executive Independent Director
Deepika Pakianathan
Non-Executive Independent Director
Brian Schwartz
No Data
No Data
About MREO
Mereo BioPharma Group plc is a United Kingdom-based biopharmaceutical company. The Company is focused on the development of therapeutics that aim to improve outcomes for oncology and rare diseases and focuses on commercializing selected rare disease programs. Its portfolio consists of six clinical-stage product candidates two of which, Etigilimab (MPH-313) and Alvelestat (MPH-966), are in ongoing clinical studies. Its lead oncology product candidate, MPH-313 is an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody. Its second oncology product, Navicixizumab (OMP-305B83) is used for the treatment of late line ovarian cancer. Its rare disease product candidates are Alvelestat, is for the treatment of severe alpha-1 antitrypsin deficiency (AATD). Its Setrusumab (BPS-804) is an antibody designed to inhibit sclerostin, a protein that inhibits the activity of bone-forming cells. Its other product candidates include Acumapimod (BCT-197) and Leflutrozole (BGS-649).

Webull offers kinds of Mereo BioPharma Group plc - ADR stock information, including NASDAQ:MREO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MREO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MREO stock methods without spending real money on the virtual paper trading platform.